A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project

被引：6
|
作者：
Lentz, Steven R. [1 ]
Tandra, Anand [2 ]
Gut, Robert Z. [3 ]
Cooper, David L. [3 ]
机构：
[1] Univ Iowa, Dept Internal Med, Div Hematol Oncol & Blood & Marrow Transplantat, C32 GH,200 Hawkins Dr, Iowa City, IA 52242 USA
[2] Hematol Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA
[3] Novo Nordisk Inc, Clin Med & Regulatory Affairs, Princeton, NJ USA
来源：
JOURNAL OF BLOOD MEDICINE | 2014年 / 5卷
关键词：
D O I：
10.2147/JBM.S55216
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 3
页数：3
相关论文
共 48 条
  • [1] A Novel Approach to Capturing Post-Marketing Safety Information On Recombinant Factor VIIa (rFVIIa) in Acquired Hemophilia: Final Data From the Acquired Hemophilia Surveillance (AHS) Project
    Lentz, Steven R.
    Tandra, Anand
    Gut, Robert Z.
    Cooper, David L.
    [J]. BLOOD, 2012, 120 (21)
  • [2] A NOVEL MECHANISM OF CAPTURING POST-MARKETING SAFETY INFORMATION ON RECOMBINANT FACTOR VIIA (RFVIIA) IN THE RARE DISORDER ACQUIRED HEMOPHILIA: THE ACQUIRED HEMOPHILIA SURVEILLANCE (AHS) PROJECT
    Lentz, S.
    Tandra, A.
    Doucette, K.
    Cooper, D. L.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A60 - A60
  • [3] The Acquired Hemophilia Surveillance (AHS) Project: A Novel Mechanism of Capturing Post-Marketing Safety Information on rFVIIa (NovoSeven®RT) In Acquired Hemophilia
    Lentz, Steven R.
    Tandra, Anand
    Peters, Tracy J.
    Cooper, David L.
    [J]. BLOOD, 2010, 116 (21) : 1508 - 1508
  • [4] Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia
    Abshire, Thomas
    [J]. SEMINARS IN HEMATOLOGY, 2008, 45 (02) : S3 - S6
  • [5] THE USE OF RECOMBINANT FACTOR VIIA IN A PATIENT WITH ACQUIRED HEMOPHILIA-A UNDERGOING SURGERY
    DOUGHTY, HA
    NORTHEAST, A
    SKLAIR, L
    ROQUES, T
    YOUNG, AE
    SAVIDGE, GF
    HUNT, BJ
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (02) : 125 - 128
  • [6] Ischemic stroke after recombinant factor VIIa treatment in acquired hemophilia A patient
    Katgi, Abdullah
    Ataca, Pinar
    Kahraman, Selda
    Piskin, Ozden
    Ozcan, Mehmet A.
    Demirkan, Fatih
    Ozsan, Guner H.
    Undar, Bulent
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (01) : 69 - 70
  • [7] The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A
    Okayama, Yusuke
    Bingo, Masato
    Sakatoku, Kazuki
    Okamura, Hiroshi
    Nanno, Satoru
    Nishimoto, Mitsutaka
    Nakashima, Yasuhiro
    Koh, Hideo
    Hino, Masayuki
    Nakamae, Hirohisa
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2023, 34 (06) : 419 - 422
  • [8] United States Post-Marketing Safety (PMS) Study of rpFVIII in Patients with Acquired Hemophilia A: Preliminary Data
    Crea, R.
    Huang, Jui-Fu
    Bajwa, Naghmana
    Gringeri, Alessandro
    [J]. BLOOD, 2017, 130
  • [9] Treatment of acquired factor VIII inihibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia
    Acquila, M
    Pasino, M
    Lanza, T
    Bottini, F
    Molinari, AC
    Bicocchi, MP
    [J]. HAEMATOLOGICA, 2004, 89 (06) : 759 - 760
  • [10] Pharmacological Concentrations of Recombinant Factor VIIa Restores Hemostasis in Acquired Hemophilia Primarily Independent of Tissue Factor
    Keshava, Shiva
    Sundaram, Jagan
    Rajulapati, Anuradha
    Pendurthi, Usha R.
    Rao, L. Vijaya Mohan
    [J]. BLOOD, 2015, 126 (23)
12345